Vita 34 sets course for accelerated growth in new business areas with changes to the Executive Board

0

DGAP-News: Vita 34 AG / Key word(s): Personnel/Corporate strategic decision
18.03.2022 / 20:21
The issuer is solely responsible for the content of this announcement.

Vita 34 sets course for accelerated growth in new business areas with changes to the Executive Board

– PBKM CEO Jakub Baran succeeds Dr. Wolfgang Knirsch as Chairman of the Board
– Tomasz Baran, member of the Management Board of PBKM, is appointed to the newly created position of Chief Commercial Officer (CCO) within the Management Board of Vita 34 AG

Leipzig, March 18, 2022 – Vita 34 AG (ISIN: DE000A0BL849; WKN: A0BL84), Europe’s leading cell bank, paves the way for accelerated growth in its core business and accelerates development in its new business areas of cell drug production / viral vectors (CDMO) and cellular therapies (CAR-T therapies) with a complete overhaul of its Management Board.

With effect from March 22, 2022, Mr. Jakub Baran has been appointed to the board of directors of Vita 34 AG. He is one of the founders and chairman of the board of the Polish company PBKM, acquired last year, and was thus significantly involved in the development of the former leading stem cell bank in Europe. He takes over the role of Chairman of the Management Board from Dr. Wolfgang Knirsch, who thus leaves the Management Board and the company by mutual agreement. “Dr. Wolfgang Knirsch had a significant impact on the success of Vita 34 and led the company to a new size and efficiency. For this achievement, we would like to express our respect and gratitude to him”, emphasizes Dr. Alexander Granderath, Chairman of the Supervisory Board of Vita 34 AG. “With Jakub Baran as our new CEO, we are ushering in a new era in the company’s growth story. On the solid foundation of cell bank cash flow, we will quickly establish ourselves with our expertise gained over the years. into future markets for cell production and cell therapies and continue to grow at an accelerating rate.”

In addition, the board of directors of Vita 34 AG will be expanded by the newly created position of Chief Commercial Officer (CCO), who will in future place particular emphasis on developing the sales and marketing strategy of the new areas. of products as well as strategic business development. Mr. Tomasz Baran was appointed to the board of directors of the company as CCO also with effect from March 22, 2022. He too has been a member of the board of directors of the Polish company PBKM since 2010 and, in his role, has developed extensive sales and marketing strategies. to address the company’s new and existing customers. “Vita 34 is currently entering new markets that are just beginning to emerge, but are already experiencing rapid growth,” explains Supervisory Board Chairman Dr. Alexander Granderath. “It therefore makes more than strategic sense to have a clear focus within the board of directors on customer acquisition and business development. Tomasz Baran brings exactly the experience of his work on the board of directors of PBKM which Vita 34 now needs to optimally take advantage of the enormous momentum in the industry.”

Further information about Vita 34 AG, its subsidiaries and its range of services can be found at www.vita34.de.

Contact:
Ingo Middelmenne
Investor Relations
Vita 34 AG
Telephone: +49 (0341) 48792 – 0
Mobile: +49 (0174) 9091190
Email: ingo.middelmenne@vita34.de

Company Profile

Vita 34 was founded in Leipzig in 1997 and, following the merger with PBKM at the end of 2021, is now by far the leading cell bank in Europe and the third in the world. As the first private umbilical cord blood bank in Europe and a pioneer in cell banking, the company is a full-service cryopreservation provider offering the logistics of collection, processing and storage of umbilical cord blood stem cells , cord tissue and other postpartum tissue. Based on the expansion of its business model in 2019, Vita 34 also intends to store adult stem cells of adipose origin, as well as immune cells from peripheral blood and the development of immune cell therapies in to come up. The body’s own cells are a valuable starting material for medical cell therapy and are kept alive at temperatures of around minus 190 degrees Celsius. About 700,000 customers from more than 30 countries have already ensured the health of their families with more than 850,000 units of biological material deposited at Vita 34.

18.03.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de

Share.

Comments are closed.